cab971 (@cab_971) profile picture

Investor in stocks for 25 years.Focus on under-followed/overlooked micro/small caps set up for outsized returns.Tweets one point of view; not investment advice.

Joined August 2015
Photo by cab971 (@cab_971)Photo by cab971 (@cab_971)Photo by cab971 (@cab_971)Photo by cab971 (@cab_971)Photo by cab971 (@cab_971)Photo by cab971 (@cab_971)Photo by cab971 (@cab_971)Photo by cab971 (@cab_971)Photo by cab971 (@cab_971)Photo by cab971 (@cab_971)
$IMMP / $IMM.AU Petra Capital reit Buy and ups tgt to A$1.30 (= $9/share for $IMMP). Says stage is set for explosive 2023. New Fidelity Int’l 13G yest shows added in Q4, raising ownership to 7.74%.
1
2
3
641
$IMMP ADRs at wide 12% discount to $IMM.AU, which closed up 3.3% & above 50dma yest in Australia. $IMM.AU at .315 & AUD$ level at .6694 equals $2.11/sh for ADRs. Bell Potter in Top Pick report sees “multi-billion $ sales pot’l for uniquely acting efti”. immutep.com/investors-media/…
2
1
6
557
$IMM.AU Named Top ’23 Pick at 2 Australian firms. Chart of AUD$ that has weighed on $IMMP ADRs most of ’22 has been more constructive of late. $IMM.AU close yest at .33/sh with AUD$ at .6866 equals ~$2.27/sh for $IMMP. teapawt.net/immutep/status/1602973…
Replying to @Immutep
@Immutep is pleased to be selected as a 'top pick' by WILSONS' analyst Melissa Benson and Bell Potter Securities' analyst Tara Speranza in their respective 2023 outlook notes. #LAG3 #biotech #healthcare #equityresearch #ASX $IMM $IMMP
2
3
@Immutep We are pleased to share compelling data from TACTI-002 Phase II trial in 1st line #NSCLC at #SITC2022. A special thanks to Dr. Iams @VUMChealth for his oral presentation of our late-breaking abstract (#1470). Join our webcast today to learn more: immutep.com/files/content/in…
5
1
17
#SITC22 | Wade Iams (@VUMChealth) discusses the TACTI-002 trial of eftilagimod alpha + pembro in 1st line #NSCLC ⭐ ORR | 40% ⭐ Median DOR | 21.6 mo ⭐ Encouraging ORR + PFS in PD-L1 low pts @sitcancer #ImmunoOnc #LCSM
1
1
12
$IMMP Strong +8.5% move in $IMM.AU on >7MM sh to close at A$0.32 (15% above 50dma) on heels of late-breaking abstract oral presentation at #SITC2022. Equals $2.02/sh for $IMMP. Aussie $ weakness cont to impact ADRs.
Replying to @Immutep
@Immutep's Late-Breaking Abstract has been accepted for an Oral Presentation at #SITC22 next week to report new clinical data for efti in combination with pembrolizumab in 1st line NSCLC from TACTI-002/KEYNOTE-798 Ph II trial. #LAG3 $IMM $IMMP ASX: https://teapawt.net/t.co/9x6o3JIVv3
2
4
$BU.TO Good to see KPMG on board as auditor to replace PWC. Burcon owns ~32% of Merit JV which includes $BG as ~29% partner. JV did >$6MM in sales in 1st yr & on track for solid yoy growth. Catalysts ahead: sunflower JV, new CEO, new collabs & higher $BG R&D plant protein spend.
“We are very pleased to have KPMG agree to come on board with us for the coming year..." Press release: Burcon Announces Annual General Meeting Date burcon.ca/2022/10/burcon-ann…
1
4
$IMMP Regeneron, Immutep Talk LAG-3 as ESMO Highlights New I-O Approaches. $IMM.AU unique MOA via #LAG3: “We activate APCs…which are involved in generating more CD8 & CD4 T cells and more NK cells…” so “potentially more targets for anti-PD-1 to work on.” biospace.com/article/regener…
1
1
9
$IMMP More on unique attributes of $IMM.AU lead clinical candidate, efti, to activate adaptive/innate system from conf. Covered broad #LAG3 pipeline & strong clinical results from efti+Keytruda vs $MRK Keytruda mono in NSCLC & HNSCC across all PD-L1 levels teapawt.net/immutep/status/1576416…
Mark Voigt, CEO of @Immutep presented at the Ladenburg Thalmann Healthcare Conference 2022 last week, covering the clinical development strategy for #efti. A replay is available here: https://teapawt.net/t.co/Xn5igWjgrl #immunotherapy #LAG3 $IMM $IMMP
1
1
5
$IMMP On heels of Fast Track news, good to see 3 abstracts at #SITC2022 incl initial data from triple combo trial that may capitalize on efti’s synergy w both chemo & IO (Keytruda) plus a Late Breaking Abstract (more details on Nov 2 as per press release) globenewswire.com/news-relea…
1
4
$IMMP Jefferies ups tgt to A$1 for $IMM.AU. Equals $6.83 for $IMMP w recent pullback in AUD$. Shares closed higher in Australia after making new 12-month low on decent volume.
$BRCN $BU.TO Good news via non-dilutive $10 million credit line from largest shareholder Firewood (wholly-owned by Director Alan Chan). Catalysts ahead incl (1) new CEO, (2) new #plantbased protein partnerships that are “progressing well”, and (3) addt’l strategic collaborations
$BRCN $BU.TO Key takeaway from $BG Q1 call: Mgmt detailed “robust pipeline of oppty’s today in range of $2BB of projects”; when asked how much was alternative proteins, CFO answered $500MM-$1BB. Reaffirms ++ outlook for plant-protein & $BRCN, Bunge’s JV partner in @MeritProteins.
1
10
$BRCN $BU.TO 10/ Another good article on Burcon/Merit’s approach to replace #methylcellulose, in particular noting “pretty remarkable gelation” with proteins that go thru their proprietary membrane filtration process. “We knew we had something special…” foodnavigator-usa.com/Articl…
1
3
$BRCN $BU.TO 1) Expect sales ramp at Merit next Q. 2) Cons #’s now inline w reality. 3) Both easy to manufacture Peazazz C + methylcellulose replacement attracting industry attn. Catalysts ahead: sunflower JV, new CEO, new collaborations & increased $BG R&D spend on plant protein
4
$IMMP Poster has 2 key datapoints not in @Immutep PR namely 1) 8.7-9.6 median OS in patients w nil to low PD-1 expression, 2) median OS not yet reached in patients w >50% PD-1 expression. Both better vs chemo. Wilson’s also does good job summarizing data buried in PR’s footnotes.
1
1
1
7
$IMMP - $MRK down ~$3 = ~$7BB mkt cap hit on Keytruda+chemoradiation combo trial fail in HNSCC. $MRK “committed” to investigating earlier stages. Efti+Keytruda combo data in 2L HNSCC compelling & helped TACTI-003 get Fast Track in 1L HNSCC. $IMMP ~$186MM mkt cap w ~$60MM cash.
2
2
2
6
$IMMP 2/ Key takeaways from update: 1) INSIGHT ~60% enrolled; 2) TACTI003 ~25% enrolled; 3) $IMMP “approached for pot’l new investigator-initiated trials as well as other pot’l collaborations for efti in various indications & combos” & “currently assessing these opportunities”.
2
1
2
$STXS Good news re: MAGIC catheter. On just existing biz leads to $46-48MM in high margin annual revs not incl system sales. Future launches incl cryoablation & Pulsed-field ablation catheters, as well as new guidewires for its >100 installed RMN systems. ir.stereotaxis.com/news-rele…
4
$IMMP Analyst at goetzpartners reit buy & ups $IMM.AU tgt to AUD$2 on >$6bb rev pot’l oppty for Efti in combo w $MRK Keytruda in NSCLC alone. Tgt equates to ~$13.70 for $IMMP.
$IMMP In Australia $IMM.AU was up ~7% to ~$2.22 sh IMMP. Tax loss selling season in Australia near end (June 30). Good interview w CEO; worth listening to all. At 37:00 mark talks of “very nice reception/reflection of data by…KOLs, PIs, potential/actual strategic partners” etc.
Episode 43 of the Benchtop Bios Podcast featuring Marc Voigt, CEO of @Immutep who discusses how the first LAG-3-targeting drug's approval, and as of ASCO 2022, Immutep’s LAG-3 asset is poised to replace IO/chemo in the front-line setting for NSCLC. Listen: lifesci.events/IMMP2
2
3
4
$IMMP With tax loss selling in Australia nearing end, $IMM.AU shares closed up slightly to .32 or $2.22 for $IMMP ADRs, that are currently trading at wider than normal 10% discount to $IMM.AU.
2